Melinta Therapeutics, a New Haven, Connecticut-based antibiotics developer, closed $67m in funding.
The round was led by Malin Corporation plc with participation from Vatera Healthcare Partners.
Proceeds from the financing will be used to complete the final Phase 3 study of delafloxacin, an investigational fluoroquinolone, currently undergoing a confirmatory Phase 3 study for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Funds will also support the potential submission of a New Drug Application (NDA) for delafloxacin for the lead indication, pursuing new indications for delafloxacin including hospital-treated community-acquired bacterial pneumonia (hCABP), and advancing a lead candidate for the company’s ESKAPE pathogen program.
Melinta Therapeutics is led by Mary Szela, chief executive officer.